Zobrazeno 1 - 10 of 201 pro vyhledávání: '"S Onali"'
1
Direct-acting antivirals used in HCV-related liver disease do not affect thyroid function and autoimmunity
Autor: R. Rodia, P. E. Meloni, C. Mascia, C. Balestrieri, V. Ruggiero, G. Serra, M. Conti, M. Loi, F. Pes, S. Onali, A. Perra, R. Littera, F. Velluzzi, S. Mariotti, L. Chessa, F. Boi
Publikováno v: Journal of Endocrinological Investigation. 46:359-366
Purpose It is well known that interferon-α (IFN-α), used for long time as the main therapy for HCV-related disease, induces thyroid alterations, but the impact of the new direct-acting antivirals (DAAs) on thyroid is not established. Aim of this pr
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d5f5f4ce1624abcfbd2c2e00768837c
https://doi.org/10.1007/s40618-022-01909-0
Zobrazit plný text záznamu
2
P455 Comparison of two strategies for the management of post-operative recurrence in Crohn’s disease patients with one clinical risk factor: a multicentre IG-IBD study
Autor: G Dragoni, F Castiglione, C Bezzio, D Pugliese, R Spagnuolo, A Viola, F Cocomazzi, A Aratari, E V Savarino, P Balestrieri, S Onali, C Viganò, D G Ribaldone, T Innocenti, A Testa, S Saibeni, G Privitera, M Milla, A Armuzzi, M C Fantini, G Fiorino
Publikováno v: Journal of Crohn's and Colitis. 17:i584-i585
Background Prevention of postoperative recurrence (POR) in Crohn’s disease (CD) after ileo-colonic (IC) resection is still a highly debated topic. Prophylactic immunosuppression after surgery is currently recommended in presence of at least one cli
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c52d5d1419717f96a60c8c158d173460
https://doi.org/10.1093/ecco-jcc/jjac190.0585
Zobrazit plný text záznamu
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
7
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
8
P613 Comparative objective effectiveness of vedolizumab and ustekinumab in a real-life cohort of active Crohn’s disease patients failure to TNF inhibitors
Autor: S Onali, D Pugliese, F A Caprioli, A Orlando, L Biancone, O M Nardone, N Imperatore, G Fiorino, M Cappello, A Viola, M B Principi, C Bezzio, A Aratari, S Carparelli, S Mazzuoli, F Manguso, L Grossi, G Bodini, D Ribaldone, G Mocci, L Minerba, A Favale, M Grova, L Scucchi, S Segato, W Fries, F Castiglione, A Armuzzi, M C Fantini
Publikováno v: Journal of Crohn's and Colitis. 16:i542-i543
Background The use of ustekinumab (UST) and vedolizumab (VDZ) as second line therapy in Crohn’s disease (CD) patients failing tumour necrosis factor alpha inhibitors is still debated. The aim of the study was to compare in a large multicentre obser
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::42911a932b023ac296a828bff2a4eaa0
https://doi.org/10.1093/ecco-jcc/jjab232.739
Zobrazit plný text záznamu
9
P150 Increased risk of ibd flare after sars-cov-2 infection. who’s the more guilty: viral infection or therapy withdrawal?
Autor: C Bezzio, A D Guarino, G Fiorino, A Armuzzi, D G Ribaldone, F Furfaro, D Pugliese, M Vernero, A Variola, V Gerardi, L Scucchi, C Viganò, F A Caprioli, J Roselli, F Coppini, S Ardizzone, S Onali, F Zingone, M Daperno, C Cortellezzi, S Carparelli, A Soriano, G Manes, S Saibeni
Publikováno v: Journal of Crohn's and Colitis. 16:i228-i229
Background In the last year, the severe adult respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic has spread rapidly around the world. The interactions between SARS-CoV-2 and inflammatory bowel disease (IBD) are so far not fully understood. In p
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::43f22758ddb7da599f593b83d0633905
https://doi.org/10.1093/ecco-jcc/jjab232.278
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje